Navigation Links
Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
Date:11/2/2009

CINCINNATI, Nov. 2 /PRNewswire/ -- Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label. Fexofenadine HCl and pseudoephredrine HCl extended-release tablets and ergocalciferol capsules represent the first two products launched in the U.S. by Winthrop U.S. under the Winthrop label with Prasco providing sales support and distribution services to Winthrop U.S. Prasco expects to begin shipping the products immediately. Specific financial terms of the agreements were not disclosed.

"We are especially proud to expand our relationship with sanofi-aventis U.S., and we are certainly pleased to provide pharmacists and consumers with these authorized generic options," said Prasco Chief Executive Officer E. Thomas Arington. "Consumers and pharmacists can have confidence in their prescription drug choices, when they have the identical product, quality, reliability of supply and the identical experience that only the brand can provide."

ALLEGRA-D and DRISDOL are registered trademarks of sanofi-aventis.

About Prasco

Prasco provides patients, pharmacists and customers with generic options that deliver the identical brand experience. The company's business model encourages competition and benefits consumers through significant cost savings.

Prasco sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers. Prasco operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and warehouse facility including DEA-approved facilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.

SOURCE Prasco Laboratories


'/>"/>
SOURCE Prasco Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
2. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
3. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
4. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
5. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
6. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
7. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
8. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
9. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
10. Clinical Logistics Enters Partnership with Gentris Corporation
11. Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):